Starting debate: EMA says rules on API materials need clarification

By Gareth Macdonald contact

- Last updated on GMT

When does API production start? EMA says clarification needed
When does API production start? EMA says clarification needed

Related tags: Pharmaceutical drug, Food and drug administration, Pharmacology

Drugmakers’ clashes with regulators over the suitability of API starting materials suggest ICH Q11 is open to interpretation and that clarification is needed according to the EMA.

As the name implies, “starting materials” are considered the first substance used in the production of an active pharmaceutical ingredient (API), which means they need to be produced in accordance with good manufacturing practice (GMP) standards.

However, while the terms are clear, the problem according to the European Medicines Agency (EMA) is that drugmakers and regulators often disagree on what constitutes a starting material as a result of flexibility built into ICH Q11 guidelines.

The EMA made the comments in a concept paper issued​ earlier this month that it said is designed to make clear what information drugmakers need to provide to justify use of a particular starting material.

Key topics covered in the concept paper include the production of APIs using complex, custom-made starting materials which, while allowing manufacturers to shorten synthesis routes, increase risk according to the Agency.

The use of external sources for any steps in a manufacturing process may lead to a higher degree of risk to quality of the active substance than would be expected were the full manufacturing process to be carried out by the applicant or a single active substance manufacturer alone​.”

The EMA also tries to address Active Substance Master Files (ASMF), explaining that data submitted to justify selection of a starting material “is often insufficient to allow adequate assessment of suitability​.”

The EMA has had the most experience of ICH Q11​ of all the major global regulatory bodies.

The London, UK-headquartered organisation adopted the scheme shortly after its release in May 2012, six months ahead of the US Food and Drug Administration (FDA).​ Japan’s Ministry of Health, Labor and Welfare (MHLW) followed suit in July this year.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars